Argenx reported that its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder, marking an unusual setback for the company. The drug was approved for generalized myasthenia gravis and has become a major seller, so the